ir.regulusrx.com
Regulus Therapeutics Inc. - Investor RelationsRegulus Therapeutics - a leading company developing microRNA therapeutics. Medicines that target the pathways of human disease.
http://ir.regulusrx.com/
Regulus Therapeutics - a leading company developing microRNA therapeutics. Medicines that target the pathways of human disease.
http://ir.regulusrx.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Tuesday
LOAD TIME
0.6 seconds
PAGES IN
THIS WEBSITE
18
SSL
EXTERNAL LINKS
73
SITE IP
206.200.251.19
LOAD TIME
0.628 sec
SCORE
6.2
Regulus Therapeutics Inc. - Investor Relations | ir.regulusrx.com Reviews
https://ir.regulusrx.com
Regulus Therapeutics - a leading company developing microRNA therapeutics. Medicines that target the pathways of human disease.
ir.regulusrx.com
Investors - Regulus Therapeutics Inc.
http://ir.regulusrx.com/index.cfm
Annual Reports and Proxies. Keeping our RGLS Family Healthy. Compensation and Financial Rewards. 4:00 PM ET on Nov 8, 2016. Nov 1, 2016. Regulus Reports Third Quarter 2016 Financial Results. Oct 25, 2016. Regulus to Release Third Quarter Financial Results on November 1, 2016. Nov 1, 2016 at 5:00 PM ET. Regulus Therapeutics Inc. Third Quarter 2016 Conference Call. Sep 7, 2016 at 2:55 PM ET. 2016 Wells Fargo Healthcare Conference. RNA therapeutics pipeline complemented by a maturing.
RSS News Feeds - Regulus Therapeutics Inc.
http://ir.regulusrx.com/rss.cfm
Annual Reports and Proxies. Keeping our RGLS Family Healthy. Compensation and Financial Rewards. Really Simple Syndication (RSS) is a format designed for sharing web content such as headlines. An RSS feed highlights fresh material for you, so you don't have to repeatedly check a site yourself for updates. How do I use RSS? Some web browsers, such as Firefox. Have RSS readers built in. There are also online aggregators, websites such as My Yahoo. To view a feed in your RSS Aggregator:. Form 4 SEC Filings.
Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights (NASDAQ:RGLS)
http://ir.regulusrx.com/releasedetail.cfm?ReleaseID=925688
Aug 4, 2015. File is in Briefcase. Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights. Advanced 'Clinical Map Initiative' with Start of Key Clinical Trials for RG-101 and RG-012-. Maintained Strong Financial Position Ending Q2 2015 with $139.4 Million in Cash-. LA JOLLA, Calif. Aug 4, 2015. June 30, 2015. And provided a summary of recent corporate highlights. The second quarter of 2015 and recent period marked an important time of progression for Regulus," said. Chief Business Of...
Events & Presentations - Regulus Therapeutics Inc.
http://ir.regulusrx.com/events.cfm
Annual Reports and Proxies. Keeping our RGLS Family Healthy. Compensation and Financial Rewards. Sep 7, 2016. 2016 Wells Fargo Healthcare Conference. 2016 Wells Fargo Healthcare Conference. Please sign up for Email alerts. Aug 2, 2016. Regulus Therapeutics Inc. Second Quarter 2016 Conference Call. Jun 27, 2016. Regulus Reports Clinical Hold of RG-101. Jun 10, 2016. Jefferies 2016 Healthcare Conference. Jun 7, 2016. Regulus Therapeutics Inc. Conference Call. File is in Briefcase. May 25, 2016. May 12, 2016.
Press Releases - Regulus Therapeutics Inc.
http://ir.regulusrx.com/releases.cfm
Annual Reports and Proxies. Keeping our RGLS Family Healthy. Compensation and Financial Rewards. Aug 31, 2016. Regulus to Present at the 2016 Wells Fargo Healthcare Conference. File is in Briefcase. Aug 9, 2016. Regulus to Present at the 2016 Wedbush PacGrow Healthcare Conference. File is in Briefcase. Aug 2, 2016. Regulus Reports Second Quarter 2016 Financial Results. LA JOLLA, Calif., Aug. 2, 2016 /PRNewswire/ - Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading t...LA JOLLA,...
TOTAL PAGES IN THIS WEBSITE
18
Biomarkers - Regulus Therapeutics
http://regulusrx.com/regulus-micromarkers
Biology & Pharmacology. Financials & Filings. Events & Presentations. Keeping our RGLS Family Healthy. Compensation and Financial Rewards. RNAs are clinically relevant therapeutic targets and may be ideally suited as biomarkers for numerous disease states. Regulus also believes that. RNA biomarkers are of significant value and may provide opportunities to develop companion diagnostics for its therapeutic candidates and any drugs developed by other companies. For example,. RNAs as biomarkers for MS. R...
RG-125 - Regulus Therapeutics
http://regulusrx.com/therapeutic-areas/rg-125
Biology & Pharmacology. Financials & Filings. Events & Presentations. Keeping our RGLS Family Healthy. Compensation and Financial Rewards. In April 2015, RG-125 (AZD4076), a GalNAc-conjugated anti-miR targeting. RNA-103/107 ( miR-103/107 ) for the treatment of Non Alcoholic Steatohepatitis ( NASH) in patients with type 2 diabetes/pre-diabetes, was selected as a clinical candidate by AstraZeneca under the companies’ strategic alliance to discover, develop and commercialize. Both NASH and NAFLD are becomin...
About microRNAs - Regulus Therapeutics
http://regulusrx.com/therapeutic-areas/road-to-the-clinic
Biology & Pharmacology. Financials & Filings. Events & Presentations. Keeping our RGLS Family Healthy. Compensation and Financial Rewards. RNAs are small naturally occurring non-coding RNAs that are 20 to 25 nucleotides in length. In 1993 and since then. RNAs have been identified in almost every species, including humans. They are highly conserved and research has shown that. RNAs function as important regulators of gene expression and play a role in multiple cellular processes. RNAs, 600 of which are co...
Paul C. Grint, M.D. - Regulus Therapeutics
http://regulusrx.com/leadership
Biology & Pharmacology. Financials & Filings. Events & Presentations. Keeping our RGLS Family Healthy. Compensation and Financial Rewards. Paul C. Grint, M.D. President and Chief Executive Officer. Senior Vice President of Human Capital. Vice President, Finance and Accounting. Victor Knopov, Ph.D. Vice President, Pharmaceutical Development. Michael Huang, M.D. Vice President, Clinical Development. John Grundy, Ph.D. Vice President, DMPK and Toxicology. Christopher Aker, J.D. Vice President, Legal Affairs.
RG-012 - Regulus Therapeutics
http://regulusrx.com/therapeutic-areas/rg-012-targeting-mir-21-for-alport-syndrome
Biology & Pharmacology. Financials & Filings. Events & Presentations. Keeping our RGLS Family Healthy. Compensation and Financial Rewards. Regulus is developing RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of miR-21 for the treatment of Alport syndrome. Alport syndrome is a life threatening genetic kidney disease with no approved therapies. In preclinical studies, RG-012 has demonstrated potent inhibition of miR-21. ATHENA Natural History Study an...
Publications - Regulus Therapeutics
http://regulusrx.com/publications
Biology & Pharmacology. Financials & Filings. Events & Presentations. Keeping our RGLS Family Healthy. Compensation and Financial Rewards. Shift of microRNA profile upon orthotopic xenografting of glioblastoma spheroid cultures. Halle, B, et al. Convection-enhanced delivery of an anti-miR is well-tolerated, preserves anti-miR stability and causes efficient target de-repression: a proof of concept. Halle B, et al. Jan;126(1):47-55.: 2016-01-01. Androsavich JR, et al. Jan 29;44(2):e13.: 2016-01-29. The Can...
About microRNAs - Regulus Therapeutics
http://regulusrx.com/about-micrornas
Biology & Pharmacology. Financials & Filings. Events & Presentations. Keeping our RGLS Family Healthy. Compensation and Financial Rewards. RNAs are small naturally occurring non-coding RNAs that are 20 to 25 nucleotides in length. In 1993 and since then. RNAs have been identified in almost every species, including humans. They are highly conserved and research has shown that. RNAs function as important regulators of gene expression and play a role in multiple cellular processes. RNAs, 600 of which are co...
About - Regulus Therapeutics
http://regulusrx.com/about-regulus
Biology & Pharmacology. Financials & Filings. Events & Presentations. Keeping our RGLS Family Healthy. Compensation and Financial Rewards. TOGETHER the Regulus team is leading the way in the discovery and development of. RNA expression is a key factor in many complex multi-factoral diseases, including inflammatory disease, fibrosis, metabolic disease and cancer. RNA therapeutics are oligonucleotides that modulate the function of. Regulus Therapeutics is located in La Jolla, California and is led by a sea...
Intellectual Property - Regulus Therapeutics
http://regulusrx.com/intellectual-property
Biology & Pharmacology. Financials & Filings. Events & Presentations. Keeping our RGLS Family Healthy. Compensation and Financial Rewards. Regulus has established a robust intellectual property portfolio relating to. RNA drug products and the modulation of. RNA to treat disease. In addition, through its founding companies, Regulus has access to broad and dominant intellectual property estates related to oligonucleotide therapeutics and chemical modifications and delivery technologies useful for. Therapeu...
RG-101 - Regulus Therapeutics
http://regulusrx.com/therapeutic-areas/rg-101
Biology & Pharmacology. Financials & Filings. Events & Presentations. Keeping our RGLS Family Healthy. Compensation and Financial Rewards. RG-101 has several important properties which may differentiate it from other therapies currently on the market for the treatment of HCV. A novel mechanism of action. Activity against all genotypes. Activity against HCV strains with mutations that cause resistance to oral direct-acting antivirals (DAAs). In a completed Phase I clinical study,. Regulus demonstrated tha...
TOTAL LINKS TO THIS WEBSITE
73
Home | Investor Information
Rediff’s Secure Internet Platform wins CIO’s Choice 2016. LJ Road # 1, Mahim (West). 169; 2018 Rediff.com US.
Investor Relations | Investor Overview | Redknee
2016 In the Media. 2015 In the Media. 2014 In the Media. 2013 In the Media. Middle East and Africa. Railway SIM Profile Management. Railway Next Generation IN. Railway Subscription Management and Data Provisioning. Managed Services and Cloud Services. Stock Quote and Chart. Management and Board of Directors. Create New Business Models. Advance the Customer Experience. Live in Action Demos. Live in Action Demos. Real-time Monetization for a Real-time World. Redknee monetizes today’s digital world, providi...
home ~ REFIRE online ~ Real Estate Intelligence Report - Europe
Declaration of PropertyCollection: create() should be compatible with ItemCollection: create() in /home/www refire/www.production/contenido/classes/class.properties.php. Declaration of PropertyItem: setField() should be compatible with Item: setField($field, $value, $safe = true) in /home/www refire/www.production/contenido/classes/class.properties.php. Declaration of DBFSCollection: create() should be compatible with ItemCollection: create() in /home/www refire/www.production/contenido/classes/class...
Investor Overview - Investors - REGENXBIO
160; 0.20. Data as of 01/12/17 4:00 pm ET. Data provided by Nasdaq. Minimum 15 minutes delayed. REGENXBIO Provides Year-End 2016 Corporate Update. REGENXBIO and Voyager Therapeutics Announce Exercise of Options for Rights to NAV Vectors. ROCKVILLE, Md. and CAMBRIDGE, Mass., Nov. 29, 2016 (GLOBE NEWSWIRE) - REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based ...On track to d...
Regions Financial Corporation - Investor Relations
Spectrum Card - Employee. Spectrum Card - Employer. 4:02 PM ET, 03/29/18. Regions is scheduled to release 1Q18 results on Friday April 20, 2018. Live teleconference and webcast beginning at 11am EST. Rarr; Learn More. Listen to the replay and read the transcript of Regions Executives present at the 2018 Credit Suisse Financial Services Conference. Rarr; Learn More. Website Terms of Use.
Regulus Therapeutics Inc. - Investor Relations
Skip to primary content. Skip to secondary content. Road to the Clinic. Biology & Pharmacology. 4:00 PM ET on Aug 17, 2015. Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting. RNA therapeutics pipeline entering clinical development, an emerging. RNA biomarkers platform to support its therapeutic programs, and a rich intellectual property estate to retain its leadership in the. RNA field have enabled the formation ...
Rehabcare : Overview
Founded in 1982, RehabCare is a leading provider of services across the post-acute continuum of care, operating programs and hospitals nationwide. RehabCare is a publicly traded company, listed on the NYSE under the symbol RHB, and is included in the Russell 2000 and Standard and Poor’s Small Cap 600 Indices. Could not find file ' aws.nasdaqomx.com irweb content3 IRXMLDATA 68 68419 Quotes.xml'. RehabCare Reports First Quarter 2011 Results. RehabCare To Announce First Quarter 2011 Results. Replication or ...
Investor Relations :: Relmada Therapeutics, Inc. (RLMDD)
REL-1017 (dextromethadone, d-Methadone). Cash position on March 31, 2015. Headcount as of December 31, 2014. Common stock outstanding at May 15, 2015. Aug 17, 2015. Relmada Therapeutics Receives Health Canada Clearance to Commence Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist. Sign Up for E-Mail Alerts. Be the first to receive breaking news. Mar 31, 2015. Officers & Directors. Slide" data-cycle-swipe="true" data-cycle-timeout= 0. Douglas J. Beck. Michael D. Becker. Dr Mangano has ...
Company Information | Remark Holdings
Skip to main navigation. Investor Relations - Horizontal. Remark Holdings (NASDAQ: MARK. Mar 29, 2018. Remark Holdings Reports Fourth Quarter and Full Year 2017 Results. Mar 23, 2018. Remark Holdings Moves Up Fourth Quarter and Full Year 2017 Earnings Call to Thursday, March 29, 2018 at 8:30 am ET. Mar 16, 2018. Remark Holdings Sets Fourth Quarter and Full Year 2017 Earnings Call for Thursday, March 29, 2018 at 4:30 pm ET. Mar 09, 2018. Mar 05, 2018. Feb 12, 2018. View all press releases.
Remy - Investors Overview
Stock Quote and Chart. 160; 0.11. Data as of 08/17/15 4:00 pm ET. Minimum 20 minute delay. August 13, 2015. Remy Announces Early Termination Of Hart-Scott-Rodino Waiting Period For Pending Acquisition Of Remy By BorgWarner. August 03, 2015. Remy International, Inc. Announces Second Quarter 2015 Results. July 30, 2015. Remy International, Inc. Announces Declaration of Dividend on Common Stock; Cancels 2nd Quarter Earnings Conference Call. There are currently no events scheduled.
Renesola - Investors - Investor Home
Stock Quote and Chart. Founded in 2005, and listed on the New York Stock Exchange in 2008, ReneSola (NYSE:SOL) is an international leading brand and technology provider of green energy products. Leveraging its global presence, expansive OEM and sales network, Renesola is well positioned to provide its highest quality green energy products and on-time services for EPC, installers, and green energy projects around the world. For more information, please visit www.renesola.com. Tel: 86-21-62809180 ext 105.
SOCIAL ENGAGEMENT